JPRN-jRCT1080224999已完成未知
Special Drug Use Surveillance for Adcetris Intravenous Infusion 50 milligrams Relapsed or refractory CD30-positive peripheral T cell lymphoma or Hodgkin Lymphoma (only pediatric patients)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Participants with relapsed or refractory lymphoma.
- •2. CD30-positive participants.
- •3. Participants who receive study drug after obtaining approval of CD30-positive PTCL indication of study drug.
排除标准
- •1. Participants with a history of severe hypersensitivity to Brentuximab Vedotin.
- •2. Participants taking bleomycin hydrochloride treatment.
研究者
相似试验
招募中
不适用
A Survey of Brentuximab Vedotin in Pediatric Participants with Hodgkin LymphomaHodgkin LymphomaJPRN-jRCT2031220244Contact for Clinical Trial Information8
未知
Unknown
ADCETRIS IV Infusion - Special drug use surveillance (all-case surveillance) Relapsed or refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphomaRelapsed or refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphomaJPRN-jRCT1080222405TAKEDA PHARMACEUTICAL COMPANY LTD.140
已完成
不适用
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Untreated CD30-Positive Hodgkin's LymphomaJPRN-jRCT1080224121Takeda Pharmaceutical Company Limited113
进行中（未招募）
不适用
Protocol Number; CLCZ696B1401Chronic Heart FailureJPRN-jRCT2031200432Sugimoto Toshiya660
招募中
不适用
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDSJPRN-UMIN000034028Janssen Pharmaceutical K.K.3